Cancer Immunotherapy: Chapter 18. Dendritic Cell Vaccines: Sipuleucel-T and Other Approaches

Cancer Immunotherapy: Chapter 18. Dendritic Cell Vaccines: Sipuleucel-T and Other Approaches
ISBN-10
0128059141
ISBN-13
9780128059142
Series
Cancer Immunotherapy
Category
Medical
Pages
684
Language
English
Published
2013-06-04
Publisher
Elsevier Inc. Chapters
Authors
Charles G. Drake, Nicholas M. Durham

Description

The idea of a preventive vaccine against cancer has been extremely attractive because of the immune system’s ability to develop specific and long-lasting immunological memory. Dendritic cells, which present antigen to T cells, sit at a critical point in the activation of the immune system because they are able to activate both B cells and T cells. The first DC vaccines were tested in humans in 1998. In 2010 the first DC vaccine was FDA approved for treatment of patients with advanced prostate cancer. This vaccine showed a survival advantage of 4.3 months. This vaccine was extremely safe, with low rates of adverse events. In this chapter we discuss the history of DC vaccines, the development of DC vaccines including Sipuleucel-T, and the future directions of DC vaccines. This includes strategies for combining DC vaccines with other therapies, including hormone therapy, additional immunotherapy, and chemotherapy.

Other editions

Similar books